pyrroles has been researched along with gemcitabine in 60 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 19 (31.67) | 29.6817 |
| 2010's | 39 (65.00) | 24.3611 |
| 2020's | 2 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Abbruzzese, J; Bruns, CJ; Buchdunger, E; Fan, D; Fidler, IJ; Harbison, MT; Ozawa, S; Radinsky, R; Solorzano, CC; Traxler, P; Tsan, R | 1 |
| Baker, CH; Buchdunger, E; Cohen, P; Fidler, IJ; Killion, JJ; Solorzano, CC; Traxler, P; Tsan, R | 1 |
| Harper, P; Khayat, D; Marx, GM; Pavlakis, N; Rixe, O; Steer, CB | 1 |
| Cropp, GF; Giaccone, G; Hoekman, K; Huisman, H; Kedde, MA; Kuenen, BC; Levi, M; Noordhuis, P; Parson, MR; Peters, GJ; Pinedo, HM; Rosen, L; Ruijter, R; Scigalla, P; Smit, EF; van der Vijgh, WJ | 1 |
| Baker, CH; Fidler, IJ; Solorzano, CC | 1 |
| Baker, CH; Bucana, CD; Fidler, IJ; Kedar, D; McCarty, MF; Tsan, R; Weber, KL | 1 |
| Baker, CH; Dinney, CP; Fidler, IJ; Kedar, D; Killion, JJ | 1 |
| Berkhof, J; Hoekman, K; Kakkar, AK; Kuenen, BC; Levi, M; Meijers, JC; Pinedo, HM; van Hinsbergh, VW | 1 |
| Fidler, IJ; Yokoi, K | 1 |
| Bevilacqua, G; Bocci, G; Boggi, U; Boschi, E; Campani, D; Danesi, R; Del Tacca, M; Esposito, I; Fasciani, A; Fioravanti, A; Marangoni, G; Mosca, F | 1 |
| du Manoir, J; Francia, G; Hicklin, DJ; Kerbel, RS; Ma, L; Rak, J; Viloria-Petit, A | 1 |
| Abbruzzese, JL; Chiao, PJ; Fleming, JB; Ishiyama, S; Melisi, D; Sclabas, GM; Tortora, G; Xia, Q | 1 |
| Cusack, JC; Houston, M; Liu, R; Ljungman, D; Palladino, MA; Sloss, CM; Wang, F; Xia, L | 1 |
| Haseke, N; Ihrler, S; Karl, A; Schöppler, G; Siebels, M; Stadler, T; Staehler, M; Stief, CG | 2 |
| Boterberg, T; Casneuf, VF; Delrue, L; Demetter, P; Peeters, M; Van Damme, N | 1 |
| Mistafa, O; Stenius, U | 1 |
| Bharthuar, A; Iyer, R; Kuvshinoff, B; LeVea, C; Litwin, A; Pearce, L | 1 |
| Wang, ZY | 1 |
| Lorenz, J; Mössner, J; Wiedmann, M; Wolf, S | 1 |
| Cedres, S; Chao, R; Felip, E; Frickhofen, N; Fuhr, HG; Gatzemeier, U; Heigener, D; Lanzalone, S; Reck, M; Ruiz-Garcia, A; Stephenson, P; Thall, A | 1 |
| Bouvet, M; Fruehauf, J; Hoffman, RM; Imagawa, DK; Katz, MH; Kaushal, S; Keleman, A; Kim, G; Romney, E; Tran Cao, HS | 1 |
| Cho, DC; McDermott, DF; Mier, JW; Pandya, SS | 1 |
| Tanji, N; Yokoyama, M | 1 |
| Bollard, CM; Buglio, D; Derenzini, E; Illés, A; Ji, Y; Jóna, A; Khaskhely, N; Medeiros, LJ; Shafer, JA; Younes, A | 1 |
| Awasthi, N; Schwarz, MA; Schwarz, RE | 1 |
| Lorenz, J; Mössner, J; Thrum, S; Wiedmann, M | 1 |
| Fu, J; Shankar, S; Srivastava, RK; Tang, SN | 1 |
| Awasthi, N; Ruan, W; Schwarz, MA; Schwarz, RE; Zhang, C | 1 |
| Bokar, JA; Brell, JM; Cooney, MM; Dowlati, A; Gibbons, J; Ivy, P; Krishnamurthi, SS; Meropol, NJ; Rath, L; Savvides, P | 1 |
| Ahola, T; Aittokallio, T; De Brabander, JK; Denisova, OV; Elliott, RM; Feng, L; Hukkanen, V; Julkunen, I; Kainov, DE; Kakkola, L; Kallio-Kokko, H; Kantele, A; Kaukinen, P; Kuivanen, S; Lampe, J; Nagaraj, A; Paavilainen, H; Saelens, X; Stenman, J; Tynell, J; Vapalahti, O; Yadav, B | 1 |
| Asmar, L; Galsky, MD; Gardner, TA; Hahn, NM; Hellerstedt, BA; Hutson, TE; Kocs, D; Lerner, SP; McKenney, SA; Melnyk, AM; O'Rourke, M; Powles, T; Rauch, M; Sonpavde, G; Vogelzang, NJ; Wang, Y; Yu, M | 1 |
| Vogelzang, NJ | 1 |
| Ahmadzadeh, A; Babaei, M; Elahi, F; Hassanpour, K; Yadollahzadeh, M | 1 |
| Chen, I; McDermott, DF; Michaelson, MD; Patyna, S; Ruiz-Garcia, A; Ryan, DP; Schwarzberg, AB; Shapiro, GI; Stephenson, P; Tye, L; Zhu, AX | 1 |
| Bansal, SS; Celia, C; Ferrari, M; Ferrati, S; Grattoni, A; Palapattu, G; Zabre, E | 1 |
| Saif, MW; Sarris, EG; Syrigos, KN | 1 |
| Blackwood, E; Cain, G; Choi, J; Epler, J; Evangelista, M; Flagella, M; Gazzard, L; Halladay, J; Jackson, PK; Jakubiak, D; Kowanetz, K; Malek, S; O'Brien, T; Ramiscal, J; Schmidt, S; Williams, K; Wong, K; Xiao, Y; Yee, S; Yen, I | 1 |
| Castiglioni, V; Cesca, M; Decio, A; Giavazzi, R; Rovida, A; Scanziani, E; Scarlato, V | 1 |
| Cataruozolo, PE; Cesari, R; Collier, M; Cortés, J; Curigliano, G; Elias, A; Goldhirsch, A; Huang, X; Kern, KA; Khosravan, R; Pivot, X | 1 |
| Blackwood, E; Del Nagro, C; Evangelista, M; Jackson, PK; Kowanetz, K; Malek, S; O'Brien, T; Ramiscal, J; Xiao, Y | 1 |
| Albanell, J; Bellmunt, J; Beltran, M; Bonfill, T; Carles, J; Gallardo, E; Galtes, S; Moya, I; Pons, F; Rodon, J; Suarez, C | 1 |
| Aulitzky, WE; Bergmann, L; Burkholder, I; Edler, L; Fuxius, S; Hartung, G; Heil, G; Köberle, D; Maute, L; Moritz, B; Richly, H; Rüssel, J; Scheulen, ME; Weidmann, E; Weigang-Köhler, K; Wörmann, B | 1 |
| Barber, J; Casbard, A; Chester, J; Cowles, R; Crabb, S; Elliott, T; Evans, J; Geldart, T; Griffiths, G; Huddart, RA; Jones, RJ; Mead, G; Protheroe, A; Smith, J | 1 |
| Cass, CE; Damaraju, VL; Kuzma, M; Mowles, D; Sawyer, MB | 1 |
| Aydin, S; Gizzi, M; Machiels, JP | 1 |
| Baba, E; Iguchi, A; Kusaba, H; Sagara, K; Sakamoto, N; Takayoshi, K; Uchino, K | 1 |
| Atkins, MB; Choueiri, TK; McDermott, DF; McKay, RR; Michaelson, MD; Olivier, KM; Signoretti, S; Song, J; Van Allen, EM; Werner, L | 1 |
| Komarov, YI; Latipova, DH; Novik, AV; Protsenko, SA; Semenova, AI; Teletaeva, GM | 1 |
| Anastasina, M; Bamford, DH; De Brabander, JK; Islam, MM; Julkunen, I; Kainov, D; Matikainen, S; Nyman, TA; Poranen, MM; Saelens, X; Šaulienė, I; Söderholm, S; Stenman, J; Tynell, J | 1 |
| Apolo, AB; De Santis, M; Galsky, MD; Leibovich, BC; Milowsky, MI; Pham, MN; Pisters, LL; Siefker-Radtke, AO; Sonpavde, G; Steinberg, GD; Sternberg, CN; Tagawa, ST; Weizer, AZ; Woods, ME | 1 |
| Askin, G; Buchy, E; Cayre, F; Couvreur, P; Desmaele, D; Gouazou, S; Mougin, J; Mura, S; Sobot, D; Stella, B; Valetti, S | 1 |
| Bespalov, MM; De Brabander, JK; Ianevski, A; Kainov, DE; Kuivanen, S; Nandania, J; Vapalahti, O; Velagapudi, V | 1 |
| Inatsu, H; Kitamura, K; Nakashima, K | 1 |
| Baldwin, G; He, H; Huynh, N; Nikfarjam, M; Wang, K; Wang, X | 1 |
| Algéo, MP; Bourdon, A; Chaire, V; Cousin, S; Italiano, A; Laroche-Clary, A; Le Loarer, F; Lucchesi, C; Rey, C; Savina, A; Shutzman, J; Toulmonde, M; Vélasco, V; Verbeke, S | 1 |
| Hou, XF; Li, K; Li, S; Wang, JF; Wu, C; Xu, SN | 1 |
| Blackwood, EM; Cousin, S; DuPree, K; Epler, J; Hamilton, E; Hollebecque, A; Infante, JR; Italiano, A; Lauchle, JO; LoRusso, PM; Lu, X; Mahrus, S; Moein, A; Moore, KN; Murray, ER; Peale, FV; Postel-Vinay, S; Schutzman, JL; Shapiro, GI; Soria, JC; Tagen, M; Tolaney, S; Toulmonde, M | 1 |
| Chong, D; Gu, Y; Guan, X; Jiang, T; Lu, Z; Song, N; Wang, JY; Wang, X; Wang, Y; Yu, R; Yu, W; Zhang, S | 1 |
| Bano, R; Gilani, MA; Hassan, A; Hayat, A; Khan, SI; Marty, JL; Zhang, H | 1 |
3 review(s) available for pyrroles and gemcitabine
| Article | Year |
|---|---|
[Bemusement and strategy on the efficacy of clinical application of targeted anticancer drugs].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Deoxycytidine; Drug Delivery Systems; Gastrointestinal Stromal Tumors; Gemcitabine; Humans; Imatinib Mesylate; Indoles; Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2009 |
Treatment of metastatic renal cell carcinoma and renal pelvic cancer.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Cisplatin; Deoxycytidine; Everolimus; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Kidney Pelvis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2011 |
Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Kidney Pelvis; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Taxoids; Ureteral Neoplasms | 2017 |
13 trial(s) available for pyrroles and gemcitabine
| Article | Year |
|---|---|
Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Indoles; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Pyrroles; Thromboembolism; Treatment Outcome | 2002 |
Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Cisplatin; Deoxycytidine; E-Selectin; Endothelial Growth Factors; Endothelium, Vascular; Female; Gemcitabine; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Lymphokines; Male; Middle Aged; Multivariate Analysis; Platelet Count; Pyrroles; Regression Analysis; Thromboembolism; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Protocols; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Female; Gemcitabine; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pyrroles; Sunitinib | 2010 |
Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrroles; Sunitinib | 2012 |
Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Indoles; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pyrroles; Sunitinib; Survival Rate; Urinary Bladder Neoplasms; Urothelium | 2013 |
Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrroles; Sunitinib | 2013 |
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pyrroles; Sunitinib; Survival Rate; Taxoids; Thrombocytopenia; Triple Negative Breast Neoplasms | 2013 |
Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Treatment Outcome | 2014 |
A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Deoxycytidine; Europe; Female; Gemcitabine; Humans; Indoles; Male; Middle Aged; Prospective Studies; Pyrroles; Sunitinib; Treatment Outcome | 2015 |
SUCCINCT: an open-label, single-arm, non-randomised, phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Indoles; Male; Middle Aged; Pyrroles; Sunitinib; Treatment Outcome; Urologic Neoplasms | 2015 |
Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Female; Gemcitabine; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib | 2015 |
CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications.
Topics: Animals; Cell Line, Tumor; Checkpoint Kinase 1; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Genes, p53; Heterografts; Humans; Mice; Mice, Knockout; Mice, Nude; Mutation; Piperidines; Pyridines; Pyrroles; Soft Tissue Neoplasms; Tumor Suppressor Protein p53 | 2018 |
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Fatigue; Female; Gemcitabine; Half-Life; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Neutropenia; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Thrombocytopenia; Treatment Outcome | 2018 |
44 other study(ies) available for pyrroles and gemcitabine
| Article | Year |
|---|---|
Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Deoxycytidine; Down-Regulation; Endothelium; ErbB Receptors; Fluorescent Antibody Technique; Gemcitabine; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Signal Transduction; Time Factors; Tumor Cells, Cultured | 2000 |
Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Division; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Endothelial Growth Factors; Enzyme Inhibitors; ErbB Receptors; Gemcitabine; Humans; Immunohistochemistry; Interleukin-8; Lymphokines; Male; Mice; Mice, Nude; Neoplasm Metastasis; Pancreatic Neoplasms; Phosphorylation; Platelet Endothelial Cell Adhesion Molecule-1; Proliferating Cell Nuclear Antigen; Pyrimidines; Pyrroles; Ribonucleotide Reductases; Signal Transduction; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Xenograft Model Antitumor Assays | 2001 |
Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: time to take stock!
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cisplatin; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Indoles; Pyrroles | 2002 |
Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; Deoxycytidine; Endothelium, Vascular; ErbB Receptors; Gemcitabine; Humans; Immunohistochemistry; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Phthalazines; Pyridines; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Xenograft Model Antitumor Assays | 2002 |
Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas.
Topics: Animals; Antineoplastic Agents; Deoxycytidine; Endothelium, Vascular; ErbB Receptors; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Paclitaxel; Pyrimidines; Pyrroles; Signal Transduction; Tumor Cells, Cultured | 2002 |
Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Renal Cell; Deoxycytidine; DNA-Binding Proteins; Down-Regulation; Endothelial Growth Factors; Enzyme Inhibitors; ErbB Receptors; Gemcitabine; Immunohistochemistry; In Situ Nick-End Labeling; Intercellular Signaling Peptides and Proteins; Kidney; Lung; Lymphokines; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Phosphorylation; Proliferating Cell Nuclear Antigen; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Signal Transduction; STAT3 Transcription Factor; Time Factors; Trans-Activators; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Blotting, Western; Butadienes; Cell Division; Cell Line, Tumor; Chromones; Deoxycytidine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gemcitabine; Humans; Hypoxia; Mitogen-Activated Protein Kinases; Morpholines; Neovascularization, Pathologic; NF-kappa B; Nitriles; Oxygen; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Signal Transduction; Sp1 Transcription Factor; Time Factors; Tyrosine | 2004 |
Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Division; Cell Line; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Endothelial Cells; Female; Gemcitabine; Humans; Immunohistochemistry; Indoles; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Pancreatic Neoplasms; Placenta; Pregnancy; Protein Kinase Inhibitors; Pyrroles; Time Factors; Tissue Culture Techniques; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2004 |
In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Coagulation; Cells, Cultured; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Endothelial Cells; Gemcitabine; Humans; Indoles; Oxindoles; Piperidines; Propionates; Pyrroles; Quinazolines; Thromboplastin | 2005 |
LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.
Topics: Animals; Anoikis; Antimetabolites, Antineoplastic; Apoptosis; Cell Movement; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Inbred C57BL; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; Pyrroles; Receptor, Transforming Growth Factor-beta Type I; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Ribonucleotide Reductases; Signal Transduction; Smad2 Protein; Survival Rate; Transforming Growth Factor beta; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cetuximab; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lactones; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyrroles; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2008 |
Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase-inhibition with sunitinib.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Kidney Tubules, Collecting; Male; Middle Aged; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2008 |
Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase inhibition with sunitinib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Kidney Tubules, Collecting; Male; Middle Aged; Prospective Studies; Pyrroles; Sunitinib; Treatment Outcome | 2009 |
Antiangiogenic versus cytotoxic therapeutic approaches in a mouse model of pancreatic cancer: an experimental study with a multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and radiotherapy.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Line, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Epidermal Growth Factor; fas Receptor; Gemcitabine; Indoles; Male; Mice; Microvessels; Neovascularization, Pathologic; Pancreatic Neoplasms; Placenta Growth Factor; Pregnancy Proteins; Protein Kinase Inhibitors; Pyrroles; Radiotherapy, Adjuvant; Sunitinib; Time Factors; Vascular Endothelial Growth Factor A | 2009 |
Statins inhibit Akt/PKB signaling via P2X7 receptor in pancreatic cancer cells.
Topics: Apoptosis; Atorvastatin; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Fluorouracil; Gemcitabine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Pyrroles; Receptors, Purinergic P2; Receptors, Purinergic P2X7; RNA, Small Interfering; Signal Transduction | 2009 |
Metastatic pancreatic adenocarcinoma and renal cell carcinoma treated with gemcitabine and sunitinib malate. A case report.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Neoplasms, Multiple Primary; Pancreatic Neoplasms; Pyrroles; Sunitinib; Treatment Outcome | 2009 |
Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance.
Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Proto-Oncogene Proteins c-akt; Pteridines; Pyrimidines; Pyrroles; Receptor, IGF Type 1 | 2010 |
Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Humans; Indoles; Inhibitory Concentration 50; Kaplan-Meier Estimate; Luminescent Proteins; Mice; Mice, Nude; Neoplasm Metastasis; Pancreatic Neoplasms; Pyrroles; Red Fluorescent Protein; Sunitinib; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
Addition of gemcitabine at the time of sunitinib resistance in metastatic renal cell cancer.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib | 2011 |
The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.
Topics: Acetylation; Apoptosis; Apoptosis Regulatory Proteins; Benzamides; Biphenyl Compounds; Boronic Acids; Bortezomib; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Hodgkin Disease; Humans; Indoles; Lymphoma, Non-Hodgkin; Neoplasm Proteins; Nitrophenols; Piperazines; Protein Processing, Post-Translational; Pyrazines; Pyridines; Pyrroles; Sulfonamides; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein | 2011 |
Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Indoles; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Polo-like kinase 1 inhibition as a new therapeutic modality in therapy of cholangiocarcinoma.
Topics: Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Deoxycytidine; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Pyrimidines; Pyrroles; RNA, Messenger | 2011 |
EGCG enhances the therapeutic potential of gemcitabine and CP690550 by inhibiting STAT3 signaling pathway in human pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Catechin; Cell Line, Tumor; Cell Movement; Cell Survival; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Piperidines; Pyrimidines; Pyrroles; Signal Transduction; STAT3 Transcription Factor | 2012 |
Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bevacizumab; Carcinoma, Pancreatic Ductal; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Female; Gemcitabine; Humans; Indoles; Mice; Mice, Nude; Mice, SCID; Neovascularization, Pathologic; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerases; Pyrroles; Sunitinib; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Obatoclax, saliphenylhalamide, and gemcitabine inhibit influenza a virus infection.
Topics: Amides; Animals; Antiviral Agents; Chlorocebus aethiops; Deoxycytidine; Dogs; Gemcitabine; Humans; Indoles; Influenza A Virus, H3N2 Subtype; Influenza, Human; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Pyrroles; RNA, Viral; Salicylates; Vero Cells; Virus Replication | 2012 |
Antiangiogenic agents, chemotherapy, and the treatment of metastatic transitional cell carcinoma.
Topics: Acute Disease; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Indoles; Male; Neoplasm Metastasis; Neutropenia; Pancreatitis; Pyrroles; Sunitinib; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2013 |
Neuroendocrine tumor of the gallbladder.
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Catheter Ablation; Cisplatin; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Female; Gallbladder; Gallbladder Neoplasms; Gemcitabine; Humans; Indoles; Middle Aged; Pyrroles; Sunitinib; Taxoids; Ultrasonography | 2013 |
Validated RP-HPLC method for the simultaneous analysis of gemcitabine and LY-364947 in liposomal formulations.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cattle; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Deoxycytidine; Drug Stability; Gemcitabine; Liposomes; Pancreatic Neoplasms; Pyrazoles; Pyrroles | 2013 |
Novel agents and future prospects in the treatment of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Anilides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Indoles; Niacinamide; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sunitinib; Treatment Outcome | 2013 |
Combination drug scheduling defines a "window of opportunity" for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; DNA Replication; Gemcitabine; Humans; Mitosis; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles | 2013 |
Chemotherapy counteracts metastatic dissemination induced by antiangiogenic treatment in mice.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Cell Movement; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Indoles; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Topotecan | 2013 |
Identification of preferred chemotherapeutics for combining with a CHK1 inhibitor.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbolines; Cell Cycle Checkpoints; Checkpoint Kinase 1; Dacarbazine; Deoxycytidine; DNA Damage; Gemcitabine; HCT116 Cells; High-Throughput Nucleotide Sequencing; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms; Neoplasms, Experimental; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Temozolomide; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2013 |
Interactions of multitargeted kinase inhibitors and nucleoside drugs: Achilles heel of combination therapy?
Topics: Axitinib; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Nucleoside Transport Proteins; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib | 2015 |
Tubulocystic carcinoma of the kidney with fatal outcome in an adolescent male.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Carcinoma, Renal Cell; Cisplatin; Deoxycytidine; Disease Progression; Fatal Outcome; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Male; Nephrectomy; Pleural Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Time Factors; Treatment Outcome | 2015 |
A case of metastatic renal cell carcinoma and bile duct carcinoma treated with a combination of sunitinib and gemcitabine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Renal Cell; Cholangiopancreatography, Magnetic Resonance; Deoxycytidine; Female; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Neoplasms, Second Primary; Polymorphism, Single Nucleotide; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
[Systemic therapy of soft tissue sarcomas].
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Ifosfamide; Indazoles; Indoles; Male; Molecular Targeted Therapy; Neoadjuvant Therapy; Niacinamide; Palliative Care; Phenylurea Compounds; Polyethylene Glycols; Pyrimidines; Pyrroles; Radiography; Sarcoma; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome | 2015 |
Immuno-modulating properties of saliphenylhalamide, SNS-032, obatoclax, and gemcitabine.
Topics: Amides; Antineoplastic Agents; Antiviral Agents; Cells, Cultured; Coinfection; Cytokines; Deoxycytidine; Gemcitabine; Humans; Immunity, Innate; Immunologic Factors; Indoles; Influenza A virus; Influenza, Human; Interferon-alpha; Lipopolysaccharides; Macrophages; Oxazoles; Phosphoproteins; Pyrroles; RNA, Viral; Salicylates; Thiazoles; Virus Replication | 2016 |
In vitro investigation of multidrug nanoparticles for combined therapy with gemcitabine and a tyrosine kinase inhibitor: Together is not better.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Indoles; Microscopy, Electron, Transmission; Nanoparticles; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2016 |
Obatoclax, saliphenylhalamide and gemcitabine inhibit Zika virus infection in vitro and differentially affect cellular signaling, transcription and metabolism.
Topics: Amides; Antiviral Agents; Brain; Caspases; Deoxycytidine; Drug Combinations; Enzyme Inhibitors; Fetus; Gemcitabine; Humans; Indoles; Metabolic Networks and Pathways; Pyrroles; Retinal Pigment Epithelium; RNA, Viral; Salicylates; Signal Transduction; Virus Replication; Zika Virus | 2017 |
Primary Cardiac Leiomyosarcoma: A 27-Month Survival with Surgery and Chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Docetaxel; Doxorubicin; Fatal Outcome; Gemcitabine; Heart Neoplasms; Humans; Ifosfamide; Indoles; Leiomyosarcoma; Life Support Care; Male; Mesna; Pyrroles; Sunitinib; Taxoids | 2017 |
Inhibition of p21 activated kinase enhances tumour immune response and sensitizes pancreatic cancer to gemcitabine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Movement; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Male; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyrroles; Random Allocation | 2018 |
Effects of obatoclax combined with gemcitabine on the biological activity of pancreatic cancer cells under hypoxic conditions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cadherins; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Deoxycytidine; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Indoles; Neoplasm Invasiveness; Pancreatic Neoplasms; Pyrroles; Tumor Suppressor Protein p53 | 2018 |
Discovery of a pyrrole-pyridinimidazole derivative as novel SIRT6 inhibitor for sensitizing pancreatic cancer to gemcitabine.
Topics: Apoptosis; Cell Line, Tumor; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Pyrroles; Sirtuins; Xenograft Model Antitumor Assays | 2023 |
An innovative and universal dual-signal ratiometric spectro-electrochemical imprinted sensor design for sandwich type detection of anticancer-drug, gemcitabine, in serum samples; cross validation via computational modeling.
Topics: Electrochemical Techniques; Electrodes; Gemcitabine; Humans; Limit of Detection; Metal Nanoparticles; Molecular Docking Simulation; Molecular Imprinting; Polymers; Pyrroles; Silver | 2024 |